Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Vincerx Pharma, a clinical-stage biopharmaceutical company, announced its participation in the SVB Securities Global Biopharma Conference taking place virtually from February 14-16, 2023. The management team will present a corporate overview and hold one-on-one meetings with investors. The presentation is scheduled for February 16, 2023, at 1:40 p.m. ET, with a webcast available for viewing. Vincerx focuses on developing innovative therapies for cancer, with a pipeline that includes enitociclib and a proprietary bioconjugation platform featuring VIP236, VIP943, and VIP924. More details can be found on their official website.

PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will present the company’s corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

SVB Securities Global Biopharma Conference Presentation Details
Date: Thursday, February 16, 2023
Time: 1:40 p.m. ET
Webcast: https://wsw.com/webcast/svb8/vinc/1621296

An archived webcast will be accessible in the Investors section of the Company’s website for approximately 90 days following the event.

About Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Vincerx) is a clinical-stage biopharmaceutical company committed to developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. Vincerx has assembled a seasoned management team with a proven track record of successful oncology drug development, approvals, and value creation. The company’s diverse pipeline consists of enitociclib, currently in Phase 1, and a proprietary modular bioconjugation platform, which includes a small molecule drug-conjugate, VIP236, in Phase 1, and preclinical next-generation antibody drug conjugates, VIP943 and VIP924.

Vincerx Pharma is based in Palo Alto, Calif., and has a research facility in Monheim, Germany. For more information, please visit www.vincerx.com.

Contacts
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

What date is Vincerx presenting at the SVB Securities Global Biopharma Conference?

Vincerx is presenting on February 16, 2023.

What time will Vincerx's presentation start on February 16?

The presentation will begin at 1:40 p.m. ET.

How can I watch Vincerx's presentation at the conference?

The presentation will be available via a webcast, which can be accessed through their official link.

What is Vincerx Pharma's focus in the biopharmaceutical industry?

Vincerx Pharma focuses on developing novel therapies to meet the medical needs of cancer patients.

What are some products in Vincerx's pipeline?

Vincerx's pipeline includes enitociclib and several drug-conjugates like VIP236, VIP943, and VIP924.